Litcius/Paper detail

Evaluation of the matrix metalloproteinase 9 (MMP9) inhibitor Andecaliximab as an Anti-invasive therapeutic in Head and neck squamous cell carcinoma

Jessica L. Allen, River A. Hames, Natalie M Mastroianni, Andrew E. Greenstein, Scott A. Weed

2022Oral Oncology24 citationsDOI

Topics & Concepts

InvadopodiaHead and neck squamous-cell carcinomaCancer researchExtracellular matrixMMP9Matrix metalloproteinaseMatrix metalloproteinase inhibitorStromal cellPathologyMedicineGentamicin protection assayTumor microenvironmentPeriostinCancerCancer cellHead and neck cancerChemistryBiologyInternal medicineCell biologyMetastasisDownregulation and upregulationTumor cellsBiochemistryGeneProtease and Inhibitor MechanismsHead and Neck Cancer StudiesCholangiocarcinoma and Gallbladder Cancer Studies
Evaluation of the matrix metalloproteinase 9 (MMP9) inhibitor Andecaliximab as an Anti-invasive therapeutic in Head and neck squamous cell carcinoma | Litcius